NextCell Pharma AB (SE:NXTCL)

:NXTCL

NXTCL

NextCell Pharma AB

RESEARCH TOOLSreports

Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr116.96M

Enterprise Valuekr106.91M

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

No Debt / Conservative Balance SheetZero reported debt materially reduces financial distress risk and preserves optionality for strategic financing. Over months this provides flexibility to fund clinical programs via equity or debt on better terms, lowering default risk and supporting long-term R&D continuity.

Multi‑year Revenue GrowthSustained top-line expansion across multiple years indicates growing market traction for core cell‑therapy offerings. Persistent revenue growth supports scalable operations and validates commercial adoption pathways critical to durable progression toward break‑even and larger market share.

Improving Free Cash Flow TrendAn improving free cash flow trend, even from negative levels, signals operational efficiencies or revenue mix gains. If sustained, this reduces reliance on external capital over months, strengthening financial resilience and enabling more predictable funding of clinical programs.

Bears Say

Persistent Large LossesDeep, recurring losses erode capital and indicate the business remains in heavy investment mode without durable profitability. Over a multi‑month horizon this limits reinvestment capacity, pressures cash runway, and forces strategic choices between slower growth or dilutive financing.

High Operating Cash BurnSignificant negative operating cash flow requires frequent external funding to sustain clinical and commercial activity. Continued burn over months raises refinancing risk, increases potential dilution, and constrains the company’s ability to scale programs without new capital.

Declining Equity And Dilution RiskMaterial decline in shareholders' equity reflects accumulated losses and prior financings, leaving a smaller capital buffer. This heightens the likelihood of future equity raises, which can dilute existing holders and weaken long‑term shareholder value if profitability is not achieved.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr116.96M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.092.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.